CREDIT SUISSE AG/ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 32 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
CREDIT SUISSE AG/ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$421,000
+84.6%
587,000
+119.0%
0.00%
Q1 2020$228,000
-96.3%
268,000
-94.3%
0.00%
-100.0%
Q4 2019$6,224,000
+142.0%
4,704,000
+81.0%
0.01%
+150.0%
Q2 2019$2,572,0002,599,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2019
NameSharesValueWeighting ↓
Context Capital Management, LLC 2,500,000$2,486,0001.44%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 20,000,000$19,894,0001.32%
SSI INVESTMENT MANAGEMENT LLC 6,154,000$6,089,0000.45%
CSS LLC/IL 7,750,000$7,713,0000.44%
Senvest Management, LLC 5,000,000$4,998,0000.44%
Antara Capital LP 2,000,000$1,989,0000.43%
LINDEN ADVISORS LP 28,527,000$28,380,0000.43%
Graham Capital Management, L.P. 10,650,000$10,579,0000.31%
WOLVERINE ASSET MANAGEMENT LLC 19,000,000$18,904,0000.25%
Polar Asset Management Partners Inc. 10,000,000$9,957,0000.18%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders